InvestSMART

Imricor Medical Systems Inc (ASX: IMR) - Announcements

Current share price for IMR : $1.450 0.07 (5.07%)+

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$520 Notice of Annual Stockholders Meeting and CDI Voting Form 27 Mar 2026 9:26AM $1.970 $1.450 fallen by 26.40%
$520 Annual Report to shareholders 27 Mar 2026 9:24AM $1.970 $1.450 fallen by 26.40%
$520 Appendix 4G and Corporate Governance Statement 27 Mar 2026 9:20AM $1.970 $1.450 fallen by 26.40%
$520 Form 10 Registration with the U.S. SEC 19 Mar 2026 9:02AM $1.860 $1.450 fallen by 22.04%
$520 FY25 Results Investor Presentation 25 Feb 2026 7:45AM $1.990 $1.450 fallen by 27.14%
$520 Imricor Releases FY25 Results 25 Feb 2026 7:45AM $1.990 $1.450 fallen by 27.14%
$520 Appendix 4E and FY25 Financial Accounts 25 Feb 2026 7:44AM $1.990 $1.450 fallen by 27.14%
$520 Na Homolce to Become 3rd Site for VISABL-VT 18 Feb 2026 9:37AM $2.040 $1.450 fallen by 28.92%
$520 FY25 Results Webinar 17 Feb 2026 9:39AM $2.060 $1.450 fallen by 29.61%
$520 Imricor Submits Advantage-MR System for FDA 510(K) Clearance 6 Feb 2026 8:53AM $1.920 $1.450 fallen by 24.48%
$520 Oklahoma Heart Institute to Become 4th US VISABL-AFL Site 3 Feb 2026 8:57AM $1.950 $1.450 fallen by 25.64%
$520 Imricor Receives FDA Clearance for NorthStar 29 Jan 2026 8:36AM $1.855 $1.450 fallen by 21.83%
$520 Imricor Q4 CY25 Quarterly Activities Report and Appendix 4C 28 Jan 2026 9:24AM $1.900 $1.450 fallen by 23.68%
$520 VCU Health to Become Third U.S. Site for VISABL-AFL 21 Jan 2026 9:13AM $2.020 $1.450 fallen by 28.22%
$520 Change in substantial holding from CGF 20 Jan 2026 4:26PM $2.020 $1.450 fallen by 28.22%
$520 Change in substantial holding 20 Jan 2026 4:19PM $2.020 $1.450 fallen by 28.22%
$520 Notification of cessation of securities - IMR 14 Jan 2026 10:19AM $1.820 $1.450 fallen by 20.33%
$520 Notification regarding unquoted securities - IMR 13 Jan 2026 9:10AM $1.850 $1.450 fallen by 21.62%
$520 FDA Clears VISION-MR Diagnostic Catheter 12 Jan 2026 8:28AM $1.580 $1.450 fallen by 8.23%
$520 Charite to Become 2nd Site for VISABL-VT 19 Dec 2025 9:47AM $1.420 $1.450 risen by 2.11%
$520 UVA Health to Become Second U.S. Site for VISABL-AFL 15 Dec 2025 8:23AM $1.420 $1.450 risen by 2.11%
$520 Initial Director's Interest Notice 10 Nov 2025 9:18AM $1.360 $1.450 risen by 6.62%
$520 Imricor Appoints Aldo Denti to Board of Directors 10 Nov 2025 8:54AM $1.360 $1.450 risen by 6.62%
$520 First in Human Ischemic VT Ablation Performed in iCMR 4 Nov 2025 9:21AM $1.365 $1.450 risen by 6.23%
$520 Cleansing Notice 28 Oct 2025 9:11AM $1.460 $1.450 fallen by 0.68%

51 - 75 of 605 results

Page 3 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.